Cornea and External Disease

Investigational therapy improves overall survival in metastatic uveal melanoma

Tebentafusp (IMCgp100; Immunocore) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in patients with metastatic uveal melanoma, according to Phase 3 clinical trial results presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. In the study, 378 patients were...